Periostin overexpression in scleroderma cardiac tissue and its utility as a marker for disease complications

Table 3 Comparison of serum periostin levels according to categorical clinical variables in SSc patients

Variable	N	periostin (ng/ml))	p value
Sex
F	88	133.0 ± 128.0	0.005
M	18	251.5 ± 201.6	0.005
Disease subtype
lcSSc	77	130.9 ± 133.7	0.001
dcSSc	29	211.9 ± 172.3	0.001
ILD
Y	58	153.1 ± 144.1	0.40
N	48	153.1± 156.0	0.40
PAH
Y	33	145.4 ± 162.3	0.47
N	73	156.6 ± 143.4	0.47
Digital ulcers, past or current
Y	14	230.5 ± 175.9	0.22
N	45	154.0 ± 149.8	0.22
Pitting scars, past or current
Y	25	174.6 ± 167.1	0.75
N	38	154.7 ± 145.1	0.75
Teleangiectasias
Y	27	161.1 ± 171.1	0.35
N	26	190.9 ± 154.3	0.35
Current/former smoker
Y	41	160.2 ± 162.2	0.96
N	51	142.4 ± 137.4	0.96
Joint contractures
Y	14	220.7 ± 165.7	0.06
N	43	140.8 ± 125.2	0.06

F Female, M Male, N Number of patients with available information, lcSSc Limited scleroderma, dcSSc Diffuse scleroderma, ILD Interstitial lung disease, PAH Pulmonary arterial hypertension, Y Yes, N No. Data are presented as mean ± standard deviation. Mann-Whitney test was used for analyses

ISSN: 1478-6362